Sagimet Biosciences (SGMT) Cash from Operations (2022 - 2026)

Sagimet Biosciences' Cash from Operations history runs 5 years deep, the most recent figure standing at 8611000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations rose 40.76% year-over-year to 8611000.0 in Q1 2026; TTM through Mar 2026 was 39725000.0, a 21.74% increase from a year earlier, with the FY2025 full-year figure at 45650000.0, down 7.58% from the prior year.
• Cash from Operations advanced to 8611000.0 in Q1 2026 per SGMT's latest filing, from 11833000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 3000.0 in Q2 2022 and bottomed at 19569000.0 in Q3 2024.
• The 5-year median for Cash from Operations is 7268500.0 (2022), against an average of 8384500.0.
• Across the five-year window, Cash from Operations slumped 190566.67% in 2023 and jumped 47.98% in 2025, its largest moves.
• Year by year, Cash from Operations stood at 7453000.0 in 2022, then climbed by 4.96% to 7083000.0 in 2023, then sank by 55.64% to 11024000.0 in 2024, then retreated by 7.34% to 11833000.0 in 2025, then gained by 27.23% to 8611000.0 in 2026.
• Per Business Quant, the three latest SGMT Cash from Operations figures stand at 8611000.0 (Q1 2026), 11833000.0 (Q4 2025), and 10180000.0 (Q3 2025).